Project scope · Obesity · Wegovy · TurkeyEngines: OpenAI 31% · Claude 29% · Gemini 27% market share

Positioning

How do AI engines position Wegovy?

Consumer AI answers · attribute-level perception versus Mounjaro, Ozempic and bariatric surgery.

Dominant attribute

Convenience

Wegovy's highest score — 98

Weakest attribute

Access / availability

Largest improvement area — 49

Positioning statement

Wegovy occupies a 'proven, convenient injection' territory. Its strongest differentiation is evidence strength and safety profile; the main vulnerability is access and reimbursement narrative, especially in local Turkish market discussions.

All engines · Consumer AI · Turkey

Overall — attribute radar and audience comparison

Same attribute list, same order, in both charts.

Attribute radar · Wegovy vs competitors

Consumer vs Professional positioning

Consumer AIProfessional AI
Efficacy
86
90
Safety
78
86
Tolerability
69
67
Convenience
98
93
Guideline position
71
81
Evidence strength
76
96
Patient suitability
71
74
Access / availability
49
42

OpenAI — attribute radar and audience comparison

Same attribute list, same order, in both charts.

Attribute radar · Wegovy vs competitors

Consumer vs Professional positioning

Consumer AIProfessional AI
Efficacy
81
85
Safety
81
89
Tolerability
69
67
Convenience
96
91
Guideline position
76
86
Evidence strength
78
98
Patient suitability
70
73
Access / availability
46
39

Claude — attribute radar and audience comparison

Same attribute list, same order, in both charts.

Attribute radar · Wegovy vs competitors

Consumer vs Professional positioning

Consumer AIProfessional AI
Efficacy
87
91
Safety
77
85
Tolerability
65
63
Convenience
99
96
Guideline position
72
82
Evidence strength
74
94
Patient suitability
66
69
Access / availability
52
45

Gemini — attribute radar and audience comparison

Same attribute list, same order, in both charts.

Attribute radar · Wegovy vs competitors

Consumer vs Professional positioning

Consumer AIProfessional AI
Efficacy
83
87
Safety
77
85
Tolerability
71
69
Convenience
99
97
Guideline position
67
77
Evidence strength
75
95
Patient suitability
72
75
Access / availability
52
45